Technical Guidance: Angiotensin I/II (1-5) for Renin-Angiotensin System Research

What This Product Solves

Angiotensin I/II (1-5) (Asp-Arg-Val-Tyr-Ile peptide) is a defined, biologically active peptide fragment derived from the first five amino acids of angiotensin I and II. In cardiovascular and renal research, it serves as a controlled reagent for modeling blood pressure regulation and aldosterone release within the renin-angiotensin system (RAS). The compound supports experimental workflows requiring precise manipulation of vasoconstrictor peptide fragments, enabling reproducible studies on hypertension, renal function, and related signaling pathways (source: internal_article). Angiotensin I/II (1-5) is not intended for use outside of these validated domains and should not be applied to unrelated peptide or signaling studies.

Protocol Parameters

• assay: Stock solution preparation
  value_with_unit: ≥66.5 mg/mL in DMSO; ≥69.5 mg/mL in ethanol
  applicability: Preparation of concentrated stock solutions for RAS modeling in cardiovascular and renal assays
  rationale: The compound is insoluble in water; high solubility in DMSO and ethanol enables accurate dosing and minimizes precipitation in experimental setups
  source_type: product_spec (product_spec)
• assay: Storage conditions
  value_with_unit: -20°C
  applicability: Long-term storage of solid compound and prepared solutions
  rationale: Low temperature preserves peptide integrity and minimizes degradation, ensuring reproducibility across experiments
  source_type: product_spec (product_spec)
• assay: Application domain
  value_with_unit: Cardiovascular and renal physiology workflows only
  applicability: Modeling blood pressure regulation, aldosterone signaling, and RAS pathway interactions
  rationale: The Asp-Arg-Val-Tyr-Ile peptide fragment's mechanistic role is limited to defined RAS contexts; application to unrelated pathways or signaling domains is not supported
  source_type: workflow_recommendation (internal_article)

Workflow Setup and QC Checklist

• Solubility assessment: Always dissolve Angiotensin I/II (1-5) in DMSO or ethanol at concentrations up to the solubility limits stated above. Do not attempt to dissolve directly in aqueous buffers to avoid incomplete dissolution and inconsistent dosing (source: product_spec).
• Peptide handling: Work in a low-humidity environment and minimize freeze-thaw cycles by aliquoting stock solutions upon initial dissolution. Thaw only immediately prior to use.
• Control design: Include vehicle controls (DMSO or ethanol) matched to the experimental concentration in all assays to account for solvent effects.
• Application restriction: Verify that each experiment is scoped to cardiovascular or renal endpoints reliant on RAS pathway integrity (source: internal_article).
• Documentation: Record batch numbers, dissolution times, and lot-specific characteristics for each experimental run to support reproducibility and troubleshooting.

Common Failure Modes and Fixes

• Incomplete dissolution: If undissolved solids persist after mixing in DMSO or ethanol, increase mixing time or use gentle sonication. Never force dissolve in water or buffer; refer to solubility limits in the product dossier.
• Peptide degradation: Peptide instability can result from repeated freeze-thaw cycles or prolonged storage at temperatures above -20°C. Mitigate this by aliquoting stocks and maintaining cold-chain protocols during handling.
• Off-target effects: Using Angiotensin I/II (1-5) outside validated RAS models may result in uninterpretable or spurious data. Cross-check all experimental designs to ensure mechanistic relevance to blood pressure regulation or aldosterone signaling (internal_article).
• Solvent interference: If vehicle controls show activity, re-confirm solvent lot purity and ensure matched solvent concentrations across all conditions.

Scope and Limitations

This product is strictly limited to renin-angiotensin system research, including blood pressure regulation peptide modeling and aldosterone release stimulation workflows. Its application outside cardiovascular and renal experimental domains is not supported due to the specific mechanistic action and solubility profile of the Asp-Arg-Val-Tyr-Ile peptide fragment (internal_article). Researchers should avoid attempts to use this reagent in unrelated peptide or general signaling studies, as neither the functional role nor the physicochemical properties are validated for such contexts.

Conclusion

Angiotensin I/II (1-5) (SKU A1047) offers a well-defined, mechanistically relevant Asp-Arg-Val-Tyr-Ile peptide fragment for controlled RAS modeling in hypertension and renal function research. Adherence to specified solubility, storage, and domain restrictions is essential for reproducibility and reliability. For further technical specifications and sourcing, refer to the APExBIO product page (Angiotensin I/II (1-5)).